<DOC>
	<DOCNO>NCT02807207</DOCNO>
	<brief_summary>The primary objective evaluate cardiac safety single oral dose ( 400 mg ) pacritinib compare placebo QT calculate use Fridericia correction ( QTcF ) interval healthy subject .</brief_summary>
	<brief_title>To Evaluate Cardiac Safety PK Following Single Oral Dose Administration Pacritinib Healthy Subjects</brief_title>
	<detailed_description>This randomize , pacritinib- versus placebo-blind , placebo- active-controlled , single-dose , single-center , 3-period crossover study evaluate cardiac safety single 400-mg dose pacritinib compare placebo , characterize PK pacritinib major human metabolites pacritinib . The study blind pacritinib placebo , open-label moxifloxacin . Subjects receive 3 treatment ( 400 mg pacritinib , placebo , 400 mg moxifloxacin ) crossover fashion . Each treatment administer monotherapy 1 3 treatment period 7-day washout period administration study medication . Screening occur 28 day Check-in ( Day -1 ) Period 1 . On Day -1 Period 1 , subject check Clinical Research Unit ( CRU ) baseline assessment confine CRU remainder study Study Completion ( Day 22 ) /Early Termination . Continuous 12-lead cardiodynamic ECG monitoring record perform predose ( least 1 hour administration study medication ) 24 hour administration study medication , 15 minute every 12 hour ( Days 2 7 period ) . Blood sample PK analysis also collect predose ( Hour 0 ) cardiodynamic ECG timepoint postdose . Safety endpoint ( eg , adverse event [ AEs ] , clinical laboratory evaluation , vital sign ) monitor throughout period . Subjects discharge Study Completion ( Day 22 ) . Subjects scheduled return Follow-up Visit 14 day ( ±3 day ) later Day 36 .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>1. healthy male female , 18 55 year age , inclusive , nontobacco user ; 2. BMI range 18.0 32.0 kg/m2 , inclusive ; 3. normal clinically significant 12lead ECG , opinion Investigator ; 4. heart rate 45 90 beat per minute ( bpm ) , inclusive , 5 minute supine position ; 5. mean systolic blood pressure &lt; 141 mmHg mean diastolic blood pressure &lt; 90 mmHg , average value take duplicate Screening ( repeat duplicate set may perform Screening ) ; 6. good health , determine clinically significant finding medical history , physical examination , vital sign ; 7 . 7. clinical laboratory evaluation ( include clinical chemistry panel [ fast least 10 hour ] , CBC , UA ) within reference range test laboratory , unless deem clinically significant Investigator ; 8. negative test select drug abuse ( include alcohol ) Screening Checkin ( Day 1 Period 1 ) ; 9. negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] hepatitis C virus antibody [ antiHCV ] ) negative HIV antibody screen ; 10. female must nonpregnant nonlactating , females childbearing potential must postmenopausal least 1 year surgically sterile ( eg , tubal ligation , hysterectomy ) least 90 day , agree use , time signing inform consent 10 day prior Checkin ( Day 1 ) Period 1 30 day Study Completion ( Day 22 ) /ET , one follow form contraception : nonhormonal intrauterine device ( IUD ) spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( eg , NuvaRing® ) ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner ; abstinence . Oral , implantable , transdermal , injectable contraceptive may use time sign informed consent 10 day prior Checkin ( Day 1 ) Period 1 14 day final dose administration . For female , pregnancy test result must negative Screening Checkin ( Day 1 ) Period 1 ; 11. male either sterile agree use , Checkin ( Day 1 ) Period 1 90 day follow Study Completion ( Day 22 ) /ET , one follow approve method contraception : male condom spermicide ; sterile sexual partner ; use female sexual partner IUD spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ; diaphragm spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive . Subjects refrain sperm donation Checkin ( Day 1 ) Period 1 90 day follow Study Completion ( Day 22 ) /ET ; 12. able comprehend willing sign Informed Consent Form ( ICF ) . 1. presence follow electrocardiographic abnormality base safety ECG Screening : 1 . QTcF interval &gt; 450 msec 2. unusual Twave morphology ( bifid Twave ) flatten low voltage Twaves 3 . PR interval &gt; 210 msec &lt; 110 msec 4. evidence second thirddegree atrioventricular block 5. electrocardiographic evidence complete leave bundle branch block ( LBBB ) , right bundle branch block , incomplete LBBB intraventricular conduction delay QRS duration &gt; 110 msec ; 2. history syncope , cardiac arrest , cardiac arrhythmia , torsades de pointes , structural heart disease , family history long QT syndrome , ongoing cardiac dysrhythmias National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) grade &gt; 3.0 ; 3. history clinical manifestation clinically significant cardiovascular , pulmonary , hepatic ( eg , hepatitis ) , renal , hematologic , gastrointestinal ( eg , celiac disease , peptic ulcer , gastroesophageal reflux , inflammatory bowel disease ) , metabolic , allergic , dermatological , neurological , psychiatric disorder ( determined Investigator ; appendectomy cholecystectomy consider clinically significant disease ) ; 4. significant abnormality liver function test ( any/all alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase &gt; 1.5 x upper limit normal [ ULN ] ; gammaglutamyl transferase &gt; 2 x ULN ; total bilirubin &gt; 1.3 x ULN ) , kidney function test ( serum creatinine &gt; ULN ) , hypokalemia ( define serum potassium &lt; 3.0 mEq/L ) persistent refractory correction , hypomagnesemia ( define serum magnesium &lt; 1.4 mEq/L ) ; 5. history malignancy , except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp ; 6. history significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator ; 7. history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug except appendectomy hernia repair allow ; 8. history Gilbert 's Syndrome ; 9. history presence abnormal ECG , , Investigator 's opinion , clinically significant ; 10. history alcoholism drug addiction within 1 year prior Checkin ( Day 1 ) Period 1 ; 11. use tobacco nicotinecontaining product within 6 month prior Checkin ( Day 1 ) Period 1 entire study ; 12. consumption alcohol caffeinecontaining food beverages 72 hour prior Screening entire study ; 13. consumption grapefruitcontaining food beverage potent cytochrome P450 ( CYP ) 3A4 inhibitor 72 hour prior Screening entire study ; 14. participation investigational study drug trial receipt investigational study drug occur within 5 halflives 30 day prior Checkin ( Day 1 ) Period 1 , whichever longer , entire study ; 15. use oral , implantable , injectable , transdermal contraceptive within 10 day prior Checkin ( Day 1 ) Period 1 time signing inform consent ( female ) 14 day final dose administration ; 16. use prescription medication and/or product within 14 day prior Checkin ( Day 1 ) Period 1 entire study ; 17. use overthecounter , nonprescription medication , vitamin , mineral within 7 day prior Checkin ( Day 1 ) Period 1 entire study ; 18. use phytotherapeutic/herbal/plantderived preparation within 7 day prior Checkin ( Day 1 ) Period 1 entire study ; 19. poor peripheral venous access ; 20. donation blood 30 day prior Screening Study Completion ( Day 22 ) /ET , inclusive , plasma 2 week prior Screening Study Completion ( Day 22 ) /ET , inclusive ; 21. receipt blood product within 2 month prior Checkin ( Day 1 ) Period 1 ; 22. diarrhea vomit Screening period Checkin ( Day 1 ) Period 1 ; 23. acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>To Study pharmacokinetics Cardiac safety pacritinib study</keyword>
</DOC>